Empirical Wealth Management
SPRY icon

Empirical Wealth Management’s ARS Pharmaceuticals SPRY Stock Holding History

Empirical Wealth Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-39,579
Closed -$317K – 1228
2026
Q2 		$317K Buy
39,579
+8,011
+25% +$68.9K ﹤0.01% 852
2026
Q1 		$253K Buy
31,568
+9,954
+46% +$95.4K ﹤0.01% 860
2025
Q4 		$252K Buy
+21,614
New +$210K ﹤0.01% 763

Other funds holding SPRY

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Creek Drive Management Group
Creek Drive Management Group San Francisco, California $368M AUM 23.05% 1-Year Est. Return
General American Investors
General American Investors New York $1.71B AUM 30.1% 1-Year Est. Return
Pavaki Capital Management
Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return
Tejara Capital
Tejara Capital London, United Kingdom $205M AUM 0.53% 1-Year Est. Return
Landscape Capital Management
Landscape Capital Management Englewood, New Jersey $1.34B AUM 18.69% 1-Year Est. Return
Empire Life Investments
Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

Empirical Wealth Management's SPRY Position: Q3 2026 in Review

Empirical Wealth Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2026, closing a stake of 39,579 shares — an estimated $317K sold.

Empirical Wealth Management first reported a position in SPRY in Q4 2025 and held it in 3 quarters. The position peaked at $317K in Q2 2026. 88 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • Empirical Wealth Management reported no remaining ARS Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Empirical Wealth Management sold 39,579 ARS Pharmaceuticals shares in Q3 2026, an estimated $317K.
  • Empirical Wealth Management first reported a position in ARS Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Empirical Wealth Management's ARS Pharmaceuticals position peaked at $317K in Q2 2026.
  • 88 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Empirical Wealth Management's 13F filing for Q3 2026, filed 27 Oct 2026.